公开(公告)号：US20150011769A1

公开(公告)日：2015-01-08

申请号：US14350108

申请日：2012-10-02

Applicant: ALMIRALL, S.A.

Inventor： Iolanda Marchueta Hereu ,  Enrique Moyes Valls

IPC: C07D215/26

CPC classification number: C07D215/26 ,  A61K31/4704 ,  Y02P20/55

Abstract: The present invention is concerned with a process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one or a pharmaceutically acceptable salt thereof.

Abstract translation: 本发明涉及制备5-（2 - {[6-（2,2-二氟-2-苯基乙氧基）己基]氨基} -1（R） - 羟基乙基）-8-羟基喹啉-2（1H ） - 酮或其药学上可接受的盐。

公开(公告)号：US20140303126A1

公开(公告)日：2014-10-09

申请号：US14311102

申请日：2014-06-20

Applicant: ALMIRALL, S.A.

Inventor： Maria Dolors FERNANDEZ FORNER ,  Maria PRAT QUINONES ,  Maria Antonia BUIL ALBERO

IPC: C07D453/02 ,  A61K45/06 ,  A61K31/439

CPC classification number: A61K31/439 ,  A61K9/0073 ,  A61K9/0075 ,  A61K31/4745 ,  A61K31/56 ,  A61K45/06 ,  A61K47/26 ,  C07D453/02 ,  Y10S514/826 ,  A61K2300/00

Abstract: A compound according to formula (I) wherein z© is a phenyl ring, a C4 to C9 heteroaromatic compound containing one or more heteroatoms, or a naphthalenyl, 5,6,7,8-tetrahydronaphthalenyl or biphenyl group; R1, R2 and R3 each independently represent a hydrogen or halogen atom, or a hydroxy group, or a phenyl, —OR4, —SR4, —NR4R5, —NHCOR4, —CONR4R5, —CN, —NO2, —COOR4 or —CF3 group, or a straight or branched lower alkyl group which may optionally be substituted, for example, with a hydroxy or alcoxy group, wherein R4 and R5 each independently represent a hydrogen atom, straight or branched lower alkyl group, or together form an alicyclic ring; or R1 and R2 together form an aromatic, alicyclic or heterocyclic ring; n is an integer from 0 to 4; A represents a —CH2—, —CH═CR6, —CR6═CH—, —CR6R7—, —CO—, —O—, —S—, —S(O)—, SO2 or NR6— group, wherein R6 and R7 each independently represent a hydrogen atom, straight or branched lower alkyl group, or R6 and R7 together form an alicyclic ring; in is an integer from 0 to 8; provided that when m=0, A is not —CH2—; p is an integer from 1 to 2 and the substitution in the azoniabicyclic ring may be in the 2, 3 or 4 position including all possible configurations of the asymmetric carbons; B represents a group of formula (i) or (ii), wherein R10 represents a hydrogen atom, a hydroxy or methyl group; and R8 and R9 each independently represents formulae (a), (b), (c), (d) and wherein R11 represents a hydrogen or halogen atom, or a straight or branched lower alkyl group and Q represents a single bond, —CH2—, —CH2—CH2, —O—, —O—CH2—, —S—, —S—CH2— or —CH═CH—, and when (i) or (ii) contain a chiral centre they may represent either configuration; X represents a pharmaceutically acceptable anion of a mono or polyvalent acid, which shows high affinity for muscarinic M3 receptors (Hm3).

公开(公告)号：US20130125884A1

公开(公告)日：2013-05-23

申请号：US13672893

申请日：2012-11-09

Applicant: Almirall, S.A.

Inventor： Rosa LAMARCA CASADO ,  Gonzalo De Miquel SERRA

IPC: A61K9/00 ,  A61M15/00 ,  A61K45/06

CPC classification number: A61K9/0073 ,  A61K9/0075 ,  A61K31/167 ,  A61K31/439 ,  A61K31/46 ,  A61K31/58 ,  A61K45/06 ,  A61M15/0065 ,  A61K2300/00

Abstract: The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 200 micrograms aclidinium bromide.

Abstract translation: 本公开涉及用于吸入的药物组合物，其包含药学上可接受的盐的干燥粉末形式的药物组合物，其与药学上可接受的干粉载体混合，提供等量的标称剂量的等价于约200微克溴化铱的吖啶鎓。